In most cases where menstrual changes occur during weight loss, these settle as weight stabilises and the body adapts to its new metabolic state
Common adverse effects reported by participants who took the highest dose of retatrutide in the TRIUMPH-1 trial included nausea (42.4% of participants), diarrhoea (32.0% of participants), constipation (26.1% of participants) and vomiting (25.3% of participants)
doi: 10.1016/j.jim.2015.08.002 Niu H, Klem T, Yang J, et al
Meanwhile, in markets where GLP-1 obesity treatment is likely to remain entirely self-pay, patients will be attracted by the greater weight loss potential (in spite of the higher price and inferior tolerability)
SAT, subcutaneous adipose tissue
The next dividend for Roundhill GLP-1 & Weight Loss ETF is expected in December